SUPN.US Supernus Pharmaceuticals, Inc.

Healthcare Pharmaceuticals USA Stocks
29.04 USD
Close of Nov 17, 2026
21.48 33.22
Market cap
USD 6.03B
P/E
-
P/B
5.64x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SUPN.US undervalued?

Graham number

The Graham number of Supernus Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Supernus Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Supernus Pharmaceuticals, Inc. yet.

Supernus Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Supernus Pharmaceuticals, Inc.

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxon…

Full company profile